Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 12/20 | 0.48 |
| ▸ | PSEN2 | P49810 | 12/20 | 0.48 |
| ▸ | APH1B | Q8WW43 | 12/20 | 0.48 |
| ▸ | NCSTN | Q92542 | 12/20 | 0.48 |
| ▸ | APH1A | Q96BI3 | 12/20 | 0.48 |
| ▸ | PSENEN | Q9NZ42 | 12/20 | 0.48 |
| ▸ | MMP2 | P08253 | 3/20 | 0.47 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.47 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.47 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.47 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | MMP1 | P03956 | 1/20 | 0.45 |
| ▸ | MMP9 | P14780 | 1/20 | 0.45 |
| ▸ | MMP8 | P22894 | 1/20 | 0.45 |
| ▸ | MMP13 | P45452 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12502549 | 1.00 | PSEN1 (0.48) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL12502501 | 0.88 | MMP2 (0.48) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL12502956 | 0.88 | MMP2 (0.57) | MMP2ADAMTS5SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL1644151 | 0.86 | PLAU (0.47) | MMP2SLC1A3SLC1A2SLC1A1CA2 | |
| Hydrochloric Acid SCHEMBL12502502 | 0.86 | MMP2 (0.56) | MMP2ADAMTS5SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL1875644 | 0.86 | MMP2 (0.49) | MMP2ADAMTS5SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL1875539 | 0.83 | MMP2 (0.50) | MMP2ADAMTS5SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL1874090 | 0.83 | MMP2 (0.49) | MMP2ADAMTS5SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL1878137 | 0.83 | MMP2 (0.49) | MMP2ADAMTS5SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL5794550 | 0.81 | MMP2 (0.49) | MMP2ADAMTS5SLC1A3SLC1A2SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2408757-B1 | A NOVEL ALPHA-(N-SULFONAMIDO) ACETAMIDE COMPOUND INCORPORATING DEUTERIUM AS INHIBITOR OF BETA AMYLOID PEPTIDE PRODUCTION | BRISTOL MYERS SQUIBB CO (US) | 2014-06-25 | — | — | EP | disclosed |
| EP-2408450-B1 | ALPHA-(N-SULFONAMIDO)ACETAMIDE COMPOUND AS AN INHIBITOR OF BETA AMYLOID PEPTIDE PRODUCTION | BRISTOL MYERS SQUIBB CO (US) | 2013-03-13 | — | — | EP | disclosed |
| EP-2408450-B1 | ALPHA-(N-SULFONAMIDO)ACETAMIDE COMPOUND AS AN INHIBITOR OF BETA AMYLOID PEPTIDE PRODUCTION | BRISTOL MYERS SQUIBB CO (US) | 2013-03-13 | — | — | EP | disclosed |
| US-8350084-B2 | Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-08 | — | — | US | disclosed |
| US-8350084-B2 | Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-08 | — | — | US | disclosed |
| US-8350084-B2 | Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-08 | — | — | US | disclosed |
| CN-101910141-B | Alpha- (N-sulfonamido) acetamide compounds as inhibitors of beta amyloid peptide production | BRISTOL MYERS SQUIBB CO | 2012-12-19 | — | — | CN | disclosed |
| CN-102718689-A | Novel alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production | BRISTOL MYERS SQUIBB CO | 2012-10-10 | — | — | CN | disclosed |
| WO-2012106579-A1 | AMINO ACID DEHYDROGENASE AND ITS USE IN PREPARING AMINO ACIDS FROM KETO ACIDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-08-09 | — | — | WO | disclosed |
| EP-2295417-B1 | Novel intermediates useful for preparing alpha-(n-sulfonamido)acetamide compound | BRISTOL MYERS SQUIBB CO (US) | 2012-07-04 | — | — | EP | disclosed |
| US-20100240719-A1 | NOVEL ALPHA-(N-SULFONAMIDO)ACETAMIDE COMPOUNDS INCORPORATING DEUTERIUM AS INHIBITORS OF BETA AMYLOID PEPTIDE PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2010-09-23 | — | — | US | disclosed |
| EP-2205575-A1 | A NOVEL ALPHA-(N-SULFONAMIDO)ACETAMIDE COMPOUND AS AN INHIBITOR OF BETA AMYLOID PEPTIDE PRODUCTION | Bristol-Myers Squibb Company (US) | 2010-07-14 | — | — | EP | disclosed |
| US-20090227642-A1 | NOVEL ALPHA-(N-SULFONAMIDO)ACETAMIDE COMPOUND AS AN INHIBITOR OF BETA AMYLOID PEPTIDE PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2009-09-10 | — | — | US | disclosed |
| US-20090227642-A1 | NOVEL ALPHA-(N-SULFONAMIDO)ACETAMIDE COMPOUND AS AN INHIBITOR OF BETA AMYLOID PEPTIDE PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2009-09-10 | — | — | US | disclosed |
| US-20090227642-A1 | NOVEL ALPHA-(N-SULFONAMIDO)ACETAMIDE COMPOUND AS AN INHIBITOR OF BETA AMYLOID PEPTIDE PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2009-09-10 | — | — | US | disclosed |
| WO-2009058552-A1 | A NOVEL ALPHA-(N-SULFONAMIDO)ACETAMIDE COMPOUND AS AN INHIBITOR OF BETA AMYLOID PEPTIDE PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-05-07 | — | — | WO | disclosed |
| WO-2009058552-A1 | A NOVEL ALPHA-(N-SULFONAMIDO)ACETAMIDE COMPOUND AS AN INHIBITOR OF BETA AMYLOID PEPTIDE PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-05-07 | — | — | WO | disclosed |
| US-20090111858-A1 | Novel Alpha-(N-Sulfonamido)Acetamide Compound as an Inhibitor of Beta Amyloid Peptide Production | BRISTOL-MYERS SQUIBB COMPANY | 2009-04-30 | — | — | US | disclosed |
| US-20090111858-A1 | Novel Alpha-(N-Sulfonamido)Acetamide Compound as an Inhibitor of Beta Amyloid Peptide Production | BRISTOL-MYERS SQUIBB COMPANY | 2009-04-30 | — | — | US | disclosed |
| US-20090111858-A1 | Novel Alpha-(N-Sulfonamido)Acetamide Compound as an Inhibitor of Beta Amyloid Peptide Production | BRISTOL-MYERS SQUIBB COMPANY | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111858-A1 | Novel Alpha-(N-Sulfonamido)Acetamide Compound as an Inhibitor of Beta Amyloid Peptide Production | APP, BACE1, IAPP | PSEN1 5/4885PSEN2 8/4885APH1B 9/4885 |
| US-20100240719-A1 | NOVEL ALPHA-(N-SULFONAMIDO)ACETAMIDE COMPOUNDS INCORPORATING DEUTERIUM AS INHIBITORS OF BETA AMYLOID PEPTIDE PRODUCTION | APP, BACE1, PSEN1 | PSEN1 3/4885PSEN2 10/4885APH1B 6/4885 |
| US-20090227642-A1 | NOVEL ALPHA-(N-SULFONAMIDO)ACETAMIDE COMPOUND AS AN INHIBITOR OF BETA AMYLOID PEPTIDE PRODUCTION | APP, BACE1, APBA1 | PSEN1 4/4885PSEN2 9/4885APH1B 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.